Abstract
Nearly 26,000 patients were enrolled in the ONTARGET study and 5,800 patients in the TRANSCEND study, for a total of almost 32,000 people, representing a wide range of patients at high cardiovascular risk and well reflecting the situation in everyday clinical practice. The study is being conducted in seven hundred centers in forty countries around the world (twenty-three from Europe, nine from Asia, five from North and South America, as well as South Africa, Australia and New Zealand), in patients of all races, so the results will be valid. literally global.